Characterization of TAE684 as a potent LRRK2 kinase inhibitor

Leucine-rich repeat kinase 2 (LRRK2) is linked to Parkinson's disease and may represent an attractive therapeutic target. Here we report a 2,4-dianilino-5-chloro-pyrimidine, TAE684, a previously reported inhibitor of anaplastic lymphoma kinase (ALK), is also a potent inhibitor of LRRK2 kinase activity (IC(50) of 7.8nM against wild-type LRRK2, 6.1nM against the G2019S mutant). TAE684 substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type LRRK2 and G2019S mutant at a concentration of 0.1-0.3μM in cells and in mouse spleen and kidney, but not in brain, following oral doses of 10mg/kg.     

GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor

Leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for some forms of Parkinson's disease. Here we report the discovery and characterization of 2-arylmethyloxy-5-subtitutent-N-arylbenzamides with potent LRRK2 activities exemplified by GSK2578215A which exhibits biochemical IC(50)s of around 10nM against both wild-type LRRK2 and the G2019S mutant. GSK2578215A exhibits exceptionally high selectivity for LRRK2 across the kinome, substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type LRRK2 and G2019S mutant at a concentration of 0.3-1.0μM in cells and in mouse spleen and kidney, but not in brain, following intraperitoneal injection of 100mg/kg.     

西藏牦牛SRAP遗传多样性及分类进化研究

用4对SRAP分子标记引物对西藏11个牦牛类群和四川麦洼牦牛的DNA进行扩增,研究其遗传多样性和分类关系。结果表明,在335头牦牛中,共得到29个基因位点,其中有19个多态位点,多态率占65.52%。12个牦牛群体间的Nei’s遗传多样性和Shannon多样性指数分别为0.048 2和0.073 4,遗传相似系数在0.781 1-0.989 1。巴青牦牛和康布牦牛的遗传多样性指数较其他类群高,分别为0.095 5和0.090 0;桑日牦牛类群的遗传多样性指数最低,仅为0.008 5。这些结果表明,12个牦牛类群的SRAP遗传多样性较低。根据Nei’s遗传距离,利用UPGMAM构建聚类关系图结果显示,嘉黎牦牛、帕里牦牛、类乌齐牦牛、桑桑牦牛、康布牦牛、巴青牦牛、丁青牦牛、斯布牦牛和麦洼牦牛聚为一大类,然后依次才与桑日牦牛、工布江达牦牛和江达牦牛相聚在一起,显示在SRAP分子遗传标记所反映的牦牛基因组的遗传结构中,江达牦牛、工布江达牦牛和桑日牦牛与其他牦牛群体间的亲缘关系较远,牦牛的这种亲缘关系与其地理分布也不一致,说明这12个牦牛的起源、演化关系较复杂,有待于进一步研究分析。     

Effect of statin therapy on the progression of coronary atherosclerosis

ABSTRACT: BACKGROUND: An increasing number of authors employing intravascular ultrasound (IVUS) and virtual histology (VH-IVUS) have investigated the effect of statin use on plaque volume (PV) and plaque composition. However, inconsistent results have been reported. Therefore, we conducted a meta-analysis to determine the appropriate regimen of statins to effectively stabilize vulnerable coronary plaques. METHODS: Online electronic databases were carefully searched for all relevant studies. We compared mean values of PV and plaque composition between baseline and follow-up in patients receiving statin therapy. We pooled treatment effects and calculated mean differences (MD) with the 95% confidence interval (CI) using a random-effects model. By stratified analyses, we explored the influence of clinical presentation, dose and duration of statin treatment, and low-density lipoprotein-cholesterol (LDL-C) levels on the effects of statins. RESULTS: Seventeen studies involving 2,171 patients were analyzed. Statin therapy significantly decreased PV (-5.3 mm3; 95% CI: --3.3 mm3 to -7.2 mm3; P < 0.001), without heterogeneity. When considering the dose and duration of statins used, only subgroups employing a high dose and long duration demonstrated a significant reduction in PV (p < 0.001). A significant decrease in PV was noted if achieved LDL-C levels were <100 mg/dL (p < 0.001). Statin treatment could induce a twofold decrease in PV in patients with acute coronary syndrome (ACS) compared with that observed in patients with stable angina pectoris (SAP). A regressive trend was seen for necrotic core volume (MD: --2.1 mm3; 95% CI: --4.7 mm3 to 0.5 mm3, P = 0.11). However, statin use did not induce a significant change for fibrotic, fibro-fatty, or dense calcium compositions. CONCLUSIONS: Our meta-analysis demonstrated that statin therapy (especially that involving a high dose and long duration and achieving <100 mg/dL LDL-C levels) can significantly decrease PV in patients with SAP or ACS. These data suggested that statins can be used to reduce the atheroma burden for secondary prevention by appropriately selecting the statin regimen. No significant change in plaque composition was seen after statin therapy.     

Identification and characterization of a novel carboxylesterase (FpbH) that hydrolyzes aryloxyphenoxypropionate herbicides

Objective

To identify and characterize a novel aryloxyphenoxypropionate (AOPP) herbicide-hydrolyzing carboxylesterase from Aquamicrobium sp. FPB-1.

Results

A carboxylesterase gene, fpbH, was cloned from Aquamicrobium sp. FPB-1. The gene is 798 bp long and encodes a protein of 265 amino acids. FpbH is smaller than previously reported AOPP herbicide-hydrolyzing carboxylesterases and shares only 21–35% sequence identity with them. FpbH was expressed in Escherichia coli BL21(DE3) and the product was purified by Ni–NTA affinity chromatography. The purified FpbH hydrolyzed a wide range of AOPP herbicides with catalytic efficiency in the order: haloxyfop-P-methyl > diclofop-methyl > fenoxaprop-P-ethyl > quizalofop-P-ethyl > fluazifop-P-butyl > cyhalofop-butyl. The optimal temperature and pH for FpbH activity were 37 °C and 7, respectively.

Conclusions

FpbH is a novel AOPP herbicide-hydrolyzing carboxylesterase; it is a good candidate for mechanistic study of AOPP herbicide-hydrolyzing carboxylesterases and for bioremediation of AOPP herbicide-contaminated environments.

     

蝙蝠犁鼻器受体V1R基因的分子进化

哺乳动物的犁鼻嗅觉系统 (VNS)主要感知信息素,而信息素在动物的生殖和社会行为中起着重要的调控作用。为了研究蝙蝠犁鼻器受体的分子进化,我们以已发表基因组的10种蝙蝠为研究对象,采用比较基因组学方法,对蝙蝠犁鼻器受体V1R基因进行分析。研究结果显示：10种蝙蝠中都存在V1R基因。尽管在印度假吸血蝠和帕氏髯蝠中存在完整的V1R基因,但大部分蝙蝠中的V1R基因却都是假基因。进一步的分析表明,假吸血蝠中仅有的1个全长的V1R基因处于中性进化状态,揭示其犁鼻器很可能已经丧失功能;而帕氏髯蝠中3个全长的V1R基因都受到了强烈的净化选择,提示其犁鼻嗅觉功能仍然保留,这些结果和蝙蝠犁鼻器形态学研究和蝙蝠TRPC2基因的研究结果相一致。我们的研究表明大部分蝙蝠丧失了犁鼻嗅觉功能,而犁鼻器功能丧失的原因比较复杂,有待进一步研究。     

Binding to serine 65‐phosphorylated ubiquitin primes Parkin for optimal PINK1‐dependent phosphorylation and activation

Mutations in the mitochondrial protein kinase PINK1 are associated with autosomal recessive Parkinson disease (PD). We and other groups have reported that PINK1 activates Parkin E3 ligase activity both directly via phosphorylation of Parkin serine 65 (Ser⁶⁵)—which lies within its ubiquitin‐like domain (Ubl)—and indirectly through phosphorylation of ubiquitin at Ser⁶⁵. How Ser⁶⁵‐phosphorylated ubiquitin (ubiquitin^{Phospho‐Ser65}) contributes to Parkin activation is currently unknown. Here, we demonstrate that ubiquitin^{Phospho‐Ser65} binding to Parkin dramatically increases the rate and stoichiometry of Parkin phosphorylation at Ser⁶⁵ by PINK1 in vitro. Analysis of the Parkin structure, corroborated by site‐directed mutagenesis, shows that the conserved His302 and Lys151 residues play a critical role in binding of ubiquitin^{Phospho‐Ser65}, thereby promoting Parkin Ser⁶⁵ phosphorylation and activation of its E3 ligase activity in vitro. Mutation of His302 markedly inhibits Parkin Ser⁶⁵ phosphorylation at the mitochondria, which is associated with a marked reduction in its E3 ligase activity following mitochondrial depolarisation. We show that the binding of ubiquitin^{Phospho‐Ser65} to Parkin disrupts the interaction between the Ubl domain and C‐terminal region, thereby increasing the accessibility of Parkin Ser⁶⁵. Finally, purified Parkin maximally phosphorylated at Ser⁶⁵ in vitro cannot be further activated by the addition of ubiquitin^{Phospho‐Ser65}. Our results thus suggest that a major role of ubiquitin^{Phospho‐Ser65} is to promote PINK1‐mediated phosphorylation of Parkin at Ser⁶⁵, leading to maximal activation of Parkin E3 ligase activity. His302 and Lys151 are likely to line a phospho‐Ser⁶⁵‐binding pocket on the surface of Parkin that is critical for the ubiquitin^{Phospho‐Ser65} interaction. This study provides new mechanistic insights into Parkin activation by ubiquitin^{Phospho‐Ser65}, which could aid in the development of Parkin activators that mimic the effect of ubiquitin^{Phospho‐Ser65}.     

An Interconnected Channel‐Like Framework as Host for Lithium Metal Composite Anodes

Lithium (Li) metal anodes have long been counted on to meet the increasing demand for high energy, high‐power rechargeable battery systems but they have been plagued by uncontrollable plating, unstable solid electrolyte interphase (SEI) formation, and the resulting low Coulombic efficiency. These problems are even aggravated under commercial levels of current density and areal capacity testing conditions. In this work, the channel‐like structure of a carbonized eggplant (EP) as a stable “host” for Li metal melt infusion, is utilized. With further interphase modification of lithium fluoride (LiF), the as‐formed EP–LiF composite anode maintains ≈90% Li metal theoretical capacity and can successfully suppress dendrite growth and volume fluctuation during cycling. EP–LiF offers much improved symmetric cell and full‐cell cycling performance with lower and more stable overpotential under various areal capacity and elevated rate capability. Furthermore, carbonized EP serves as a light‐weight high‐performance current collector, achieving an average Coulombic efficiency ≈99.1% in ether‐based electrolytes with 2.2 mAh cm^?2 cycling areal capacity. The natural structure of carbonized EP will inspire further artificial designs of electrode frameworks for both Li anode and sulfur cathodes, enabling promising candidates for next‐generation high‐energy density batteries.